References

1. Van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia . 2012;26(9):1908-1975. doi:10.1038/leu.2012.120
2. Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. 2016. doi:10.1182/blood-2016-01
3. Tchernonog E, Faurie P, Coppo P, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: Analysis of 135 patients from the LYSA group. Ann Oncol . 2017;28(4):843-848. doi:10.1093/annonc/mdw684
4. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood . 1997;89(4):1413-1420. doi:10.1182/blood.v89.4.1413
5. Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: Not in the mouth. Clin Lymphoma, Myeloma Leuk . 2011;11(2):185-189. doi:10.1016/j.clml.2011.03.008
6. Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: A clinically heterogenous spectrum in both HIV-positive and -negative patients.Ann Oncol . 2004;15(11):1673-1679. doi:10.1093/annonc/mdh399
7. Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL. Plasmablastic Lymphoma in HIV-Positive Patients. Am J Surg Pathol . 2005;29(12):1633-1641. doi:10.1097/01.pas.0000173023.02724.1f
8. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES, Taddesse-Heath L. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features HHS Public Access. Mod Pathol . 2010;23(7):991-999. doi:10.1038/modpathol.2010.72
9. Meer S, Perner Y, McAlpine ED, Willem P. Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.Histopathology . 2020;76(2):212-221. doi:10.1111/his.13964
10. Vega F, Chang C-C, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol . 2005;18:806-815. doi:10.1038/modpathol.3800355
11. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood . 2015;125(15):2323-2330. doi:10.1182/blood-2014-10-567479
12. Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol . 2014;38(7):875-886. doi:10.1097/PAS.0000000000000234
13. Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, et al. Aggressive large B-cell lymphoma with plasma cell differentiation: Immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.Haematologica . 2010;95(8):1342-1349. doi:10.3324/haematol.2009.016113
14. Tominaga N, Katagiri S, Hamaguchi Y, et al. Plasma cell leukaemia of non-producer type with missing light chain gene rearrangement. Br J Haematol . 1988;69(2):213-218. doi:10.1111/j.1365-2141.1988.tb07624.x
15. Kyle RA, Child JA, Anderson K, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol . 2003;121(5):749-757. doi:10.1046/j.1365-2141.2003.04355.x
16. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood . 2001;97(9):2900-2902. doi:10.1182/blood.V97.9.2900
17. Dupuis MM, Tuchman SA. OncoTargets and Therapy Dovepress Non-secretory multiple myeloma: from biology to clinical management. 2016. doi:10.2147/OTT.S122241
18. Gran C, Uttervall K, Borg Bruchfeld J, et al. Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration? Eur J Haematol . 2019;103(6):588-596. doi:10.1111/ejh.13325
19. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013. Mayo Clin Proc . 2013;88(4):360-376. doi:10.1016/j.mayocp.2013.01.019
20. Greipp PR, Miguel JS, Dune BGM, et al. International staging system for multiple myeloma. J Clin Oncol . 2005;23(15):3412-3420. doi:10.1200/JCO.2005.04.242
21. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group. Blood . 1998;91(7):2501-2507. doi:10.1182/blood.v91.7.2501.2501_2501_2507
22. Andres Suarez-Londono J, Rohatgi A, Antoine-Pepeljugoski C, Braunstein MJ. Aggressive presentation of plasmablastic myeloma. 2020. doi:10.1136/bcr-2020-234436
Table 1. Laboratory findings of the peripheral blood examination at diagnosis and from the control blood test performed three months earlier. (N.A.: not available)
Figure 1. A: peripheral blood smear with an erythroblast (blue arrow) and a blastic cell (red arrow) (Wright-Giemsa, ×1000), B and C: bone marrow smear with pleomorphic blastic cells with immature chromatin and a conspicuous nucleolus. Some blast cells display a distinctive perinuclear Golgi zone (C) (Wright-Giemsa, ×1000).
Figure 2. A. Bone marrow trephine biopsy with dense diffuse infiltrate consisting of atypical plasma cells (H&E, ×400), B. IHC of CD138+ plasma cells (x400).